U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2009
364
Substance Class Protein
Created
by admin
on Mon Mar 31 20:45:24 GMT 2025
Edited
by admin
on Mon Mar 31 20:45:24 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
M95KG522R0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OFATUMUMAB
DASH   EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ARZERRA
Preferred Name English
HUMAX-CD20 2F2
Code English
HUMAX-CD20
Common Name English
OFATUMUMAB [USAN]
Common Name English
GSKI841157
Code English
HUMAX-CD20, 2F2
Code English
OFATUMUMAB [VANDF]
Common Name English
OFATUMUMAB [MART.]
Common Name English
GSK1841157
Code English
OFATUMUMAB [PURPLE BOOK CDER]
Common Name English
OFATUMUMAB [JAN]
Common Name English
OFATUMUMAB [MI]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN))(HUMAN MONOCLONAL HUMAX-CD20 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL HUMAX-CD20 .KAPPA.-CHAIN, DIMER
Common Name English
Ofatumumab [WHO-DD]
Common Name English
GSK-1841157
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN))(HUMAN MONOCLONAL HUMAX-CD20 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL HUMAX-CD20 .KAPPA.-CHAIN, DIMER
Common Name English
2F2
Common Name English
OFATUMUMAB [EMA EPAR]
Common Name English
ofatumumab [INN]
Common Name English
HUMAX-CD20-2F2
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/08/581
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
EMA ASSESSMENT REPORTS ARZERRA (AUTHORIZED: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL)
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
WHO-ATC L01XC10
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
NCI_THESAURUS C129822
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
LIVERTOX NBK548649
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
WHO-VATC QL01XC10
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
NCI_THESAURUS C141215
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
FDA ORPHAN DRUG 275809
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
NDF-RT N0000175657
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
Code System Code Type Description
LACTMED
Ofatumumab
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
INN
8606
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
NCI_THESAURUS
C66952
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
DRUG BANK
DB06650
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
USAN
WW-56
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
RXCUI
712566
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY RxNorm
DAILYMED
M95KG522R0
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
MERCK INDEX
m8132
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY Merck Index
CAS
679818-59-8
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
EVMPD
SUB25221
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
WIKIPEDIA
Ofatumumab
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
MESH
C527517
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
DRUG CENTRAL
4951
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201836
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
SMS_ID
100000089253
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
FDA UNII
M95KG522R0
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
HSDB
8170
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
PUBCHEM
6918251
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
IUPHAR
6778
Created by admin on Mon Mar 31 20:45:24 GMT 2025 , Edited by admin on Mon Mar 31 20:45:24 GMT 2025
PRIMARY
From To
1_22 1_96
1_149 1_205
1_225 3_214
1_231 2_231
1_234 2_234
1_266 1_326
1_372 1_430
2_22 2_96
2_149 2_205
2_225 4_214
2_266 2_326
2_372 2_430
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Related Record Type Details
OFATUMUMAB
TARGET -> INHIBITOR
B-LYMPHOCYTE ANTIGEN CD20
TARGET->LIGAND
Related Record Type Details
OFATUMUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Vdss PHARMACOKINETIC
MOL_WEIGHT:SEQUENCE CHEMICAL
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Molecular Formula CHEMICAL
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966